276 related articles for article (PubMed ID: 23963867)
1. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue.
Carlotto A; Hogsett VL; Maiorini EM; Razulis JG; Sonis ST
Pharmacoeconomics; 2013 Sep; 31(9):753-66. PubMed ID: 23963867
[TBL] [Abstract][Full Text] [Related]
2. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers.
Ihbe-Heffinger A; Ehlken B; Bernard R; Berger K; Peschel C; Eichler HG; Deuson R; Thödtmann J; Lordick F
Ann Oncol; 2004 Mar; 15(3):526-36. PubMed ID: 14998860
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness and cost-effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: Assessment of Nausea in Chemotherapy Research (ANCHoR), a randomised controlled trial.
Molassiotis A; Russell W; Hughes J; Breckons M; Lloyd-Williams M; Richardson J; Hulme C; Brearley S; Campbell M; Garrow A; Ryder W
Health Technol Assess; 2013 Jun; 17(26):1-114. PubMed ID: 23803562
[TBL] [Abstract][Full Text] [Related]
4. Oral mucositis in head and neck cancer: risk, biology, and management.
Sonis ST
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714511
[TBL] [Abstract][Full Text] [Related]
5. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population.
Haiderali A; Menditto L; Good M; Teitelbaum A; Wegner J
Support Care Cancer; 2011 Jun; 19(6):843-51. PubMed ID: 20532923
[TBL] [Abstract][Full Text] [Related]
6. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.
Burke TA; Wisniewski T; Ernst FR
Support Care Cancer; 2011 Jan; 19(1):131-40. PubMed ID: 20101417
[TBL] [Abstract][Full Text] [Related]
7. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea.
Sharma R; Tobin P; Clarke SJ
Lancet Oncol; 2005 Feb; 6(2):93-102. PubMed ID: 15683818
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States.
Craver C; Gayle J; Balu S; Buchner D
J Med Econ; 2011; 14(1):87-98. PubMed ID: 21241160
[TBL] [Abstract][Full Text] [Related]
9. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
10. Symptoms in Children Receiving Treatment for Cancer-Part I: Fatigue, Sleep Disturbance, and Nausea/Vomiting.
Hooke MC; Linder LA
J Pediatr Oncol Nurs; 2019; 36(4):244-261. PubMed ID: 31307321
[TBL] [Abstract][Full Text] [Related]
11. Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer.
Miller PJ; Balu S; Buchner D; Walker MS; Stepanski EJ; Schwartzberg LS
J Med Econ; 2013 Oct; 16(10):1179-89. PubMed ID: 23919632
[TBL] [Abstract][Full Text] [Related]
12. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy.
Tina Shih YC; Xu Y; Elting LS
Cancer; 2007 Aug; 110(3):678-85. PubMed ID: 17567835
[TBL] [Abstract][Full Text] [Related]
13. [Prevention and treatment of chemotherapy-induced digestive toxicities].
Boige V; Ducreux M
Bull Cancer; 2001 Feb; 88(2):163-73. PubMed ID: 11257591
[TBL] [Abstract][Full Text] [Related]
14. Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic review.
Sommariva S; Pongiglione B; Tarricone R
Crit Rev Oncol Hematol; 2016 Mar; 99():13-36. PubMed ID: 26697988
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium.
Annemans L; Strens D; Lox E; Petit C; Malonne H
Support Care Cancer; 2008 Aug; 16(8):905-15. PubMed ID: 17965891
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy.
Murphy BA
J Support Oncol; 2007 Oct; 5(9 Suppl 4):13-21. PubMed ID: 18046994
[TBL] [Abstract][Full Text] [Related]
17. WISECARE+: Results of a European study of a nursing intervention for the management of chemotherapy-related symptoms.
Kearney N; Miller M; Maguire R; Dolan S; MacDonald R; McLeod J; Maher L; Sinclair L; Norrie J; Wengström Y
Eur J Oncol Nurs; 2008 Dec; 12(5):443-8. PubMed ID: 18842457
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
Moore S; Tumeh J; Wojtanowski S; Flowers C
Value Health; 2007; 10(1):23-31. PubMed ID: 17261113
[TBL] [Abstract][Full Text] [Related]
19. Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives.
Salsman JM; Grunberg SM; Beaumont JL; Rogers M; Paul D; Clayman ML; Cella D
J Natl Compr Canc Netw; 2012 Feb; 10(2):149-57. PubMed ID: 22308514
[TBL] [Abstract][Full Text] [Related]
20. Mucositis: pathobiology and management.
Villa A; Sonis ST
Curr Opin Oncol; 2015 May; 27(3):159-64. PubMed ID: 25774860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
